SNGX: Continuing to Analyze FLASH2 Data
On May 8, 2026, Soligenix, Inc. (SNGX) announced financial results for the first quarter of 2026 and provided a business update. Following the...
84 Views
SNGX: FLASH2 Trial Recommended to Stop for Futility
On April 28, 2026, Soligenix, Inc. (SNGX) announced interim results from the Phase 3 FLASH2 trial of HyBryte in the treatment of cutaneous T cell...
109 Views
SNGX: Interim Analysis for Phase 3 CTCL Study in 2Q26
On March 31, 2026, Soligenix, Inc. (SNGX) announced financial results for the year ending December 31, 2025 and provided a business update. The...
156 Views
SNGX: Important Upcoming Readouts in Phase 3 CTCL Study
Soligenix, Inc. (SNGX) has a number of important clinical readouts and milestones ahead in 2026. We anticipate an interim analysis for the ongoing...
194 Views
SNGX: Positive Results for Phase 2a Trial in Psoriasis
On December 17, 2025, Soligenix, Inc. (SNGX) announced positive results from Cohort 3 of its ongoing Phase 2a trial of SGX302 (synthetic...
266 Views